Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin

Chemotherapy

Volumn 45, Issue 3, 1999, Pages 147-153

  Potkar, C ^a   Gogtay, N ^a   Gokhale, P ^a   Kshirsagar, N A ^a   Ajay, S ^b   Cooverji, N D ^b   Bruzzese, T ^c,d  

^a KEM HOSPITAL   (India)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c Società Prodotti Antibiotici   (Italy)

^d Societa Prodotti Antibiotici S p A   (Italy)

Author keywords

Pharmacokinetics; Rifametane; Rifampicin; SPA S 565

Indexed keywords

3 [(1 DIETHYLAMINOETHYLIDENE)AZINOMETHYL]RIFAMYCIN SV; REFAMETANE; RIFAMPICIN; RIFAMYCIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; REFERENCE VALUES; RIFAMPIN; RIFAMYCINS;

EID: 0032962134     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007176     Document Type: Article

References (12)

1. Bruzzese T, Cedro A, Dell'Acqua E, Di Nardo A, Goi A: New long-acting 3-azinomethyl rifamycins. Farmaco [Sci] 1986;41:196-204.
2. Simonetti N, Bruzzese T, Strippoli V: 'In vitro' and 'in vivo' antibacterial activity of SPA-S-565, a new rifamycin derivative. IX International Congress of Infectious and Parasitic Diseases. Munich, July 20-26, 1986, abstract 1400.
3. Strippoli V, Bruzzese T, Galli R, Simonetti N, Tronci N: The antibacterial activity of a new 3-azinomethyl-rifamycin. Farmaco [Sci] 1988; 43:619-625.
4. Zanetti S, Usai D, Nonis A, Fadda G: In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis. J Antimicrob Chemother 1996;37:357-359.
5. Marchese A, Debbia EA, Schito GC: In-vitro activity of SPA-S-565, a new rifamycin derivative, against clinical isolates of Neisseria gonorrhoeae. Can Infect Dis 1995;6(suppl C):2076.
6. Hamilton-Miller JMT, Bruzzese T, Nonis A, Shah S: Comparative anti-gonococcal activity of S-565, a new rifamycin. Int J Antimicrob Agents 1996;7:247-250.
7. Kelkar MS, Saraf AP, Bakhle DS, Nazare V, Ajay S, Hagde S, Lal HM, Cooverji ND, Bruzzese T: Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared to the conventional rifampicin. Clin Pharmacol Res 1998;18:137-143.
8. Gibaldi M, Perrier D: Pharmacokinetics. New York, Dekker, 1975.
9. Grizzle JE: The two period change-over design and its use in clinical trials. Biometrics 1965;21:467-480.
10. Curci G, Ninni A: Attuali conoscenze sulla farmacologia delle rifamicine con particolare riguardo alia farmacocinetica della rifampicina. Simp Naz Rifampicina, Roma, November 20, 1970, 18A-36A.
11. Westlake WJ: Problems associated with analysis of pharmacokinetic models. J Pharm Sci 1971;60:82.
12. Binda G, Domenichini E, Gottardi A, Orlandi B, Ortelli E, Pacini B, Fowst G: Rifampicin, a general review. Arzneimittelforschung 1971; 21:1907-1977.